June 7, 2018 News by Alice MelĆ£o, MSc #CMSC2018 ā Pharmacist Discusses Advances, Challenges in Cannabinoids Research to Treat MS Several studies have demonstrated the therapeutic potential of cannabis and its derivate products to manage the symptoms of multiple sclerosis (MS) and other neurodegenerative diseases. But there is still much to be done to enhance their use and accessibility to patients who may benefit from these therapies, according to…
June 6, 2018 News by Patricia Inacio, PhD #CMSC2018 ā Inhibiting Oxidative Stress Enzyme Promotes Resealing of Blood-Brain Barrier in MS Mouse Model Inhibiting an oxidative stress enzyme called myeloperoxidase protects the blood-brain barrier in a mouse model of multiple sclerosis (MS), limiting the migration of immune cells and halting their attack on nerve cells, researchers have found. Disruption of the blood-brain barrier is a hallmark of various disorders, including MS, and when…
June 6, 2018 News by Patricia Inacio, PhD #CMSC2018 – Gains in Functional Abilities Seen in Lemtrada-treated MS Patients Over Six Years, CARE-MS II Extension Study Shows Patients with active relapsing-remitting multiple sclerosis (MS) continue to show improvement ā lesser functional disability across a variety of measures ā and often without the need for continuous treatment after takingĀ LemtradaĀ for two years, according to six-year results from the CARE-MS II extension study. These results were shared in a…
June 5, 2018 News by Alice MelĆ£o, MSc #CMSC2018 ā Advances Made in Care of Children with MS, but Challenges Remain, Expert Says While the treatment and care of children and teenagers with multiple sclerosis (MS) has seen many developments in recent years, there are still many challenges to overcome, according to a presentation given by Brenda Banwell, MD. Banwell, who is the chief of child neurology at the Childrenās Hospital…
June 5, 2018 News by Patricia Inacio, PhD #CMSC2018 – New Phase 2 Data Supports Ublituximab in Effectively Lowering Relapses, Depleting B-cells in MS Patients New results from a Phase 2 trial evaluating TG Therapeuticsā ublituximab continue to support the therapy’s efficacy in treating relapsing forms of multiple sclerosis (MS). This investigative infusion therapy is now moving into a Phase 3 study. Treatment with 450 mg of ublituximab delivered intravenously in a rapid fashion…
May 15, 2018 News by Patricia Silva, PhD #CMSC2018 – Julie Roberts, Country Music Singer and MS Advocate, Performing at CMSC Meeting Julie Roberts, a country music singer and multiple sclerosis (MS) patient advocate, will perform at the upcomingĀ Consortium of Multiple Sclerosis Centers (CMSC)ās annual meeting,Ā the association announced Roberts, diagnosed with MS while making her second recording in 2005, will also attend CMSC sessions to learn more about…
April 9, 2018 News by Jose Marques Lopes, PhD #CMSC2018 – Closing Lecture to Focus on Best Use of DMTs When and how to best use disease-modifying therapies (DMTs) inĀ multiple sclerosisĀ depends on key treatment decisions that, partly because the number of DMTs available, can be as challenging for clinicians as they are for patients. DMTs and their optimal use will be covered in the closing lecture of the…